US FDA green light for Samsung BioLogics’ mAb production

By Flora Southey contact

- Last updated on GMT

Getty/Creative-Touch
Getty/Creative-Touch
The US FDA has granted Samsung BioLogics’ second manufacturing plant another approval for monoclonal antibody production.

Samsung BioLogics’ second facility in Incheon, South Korea – regarded​ as the world’s largest single bioproduction plant – received the manufacturing approval earlier this week.

The contract development and manufacturing organisation (CDMO) did not disclose details regarding the monoclonal antibody (mAb), but a spokesperson told us the approval “allows our clients to quickly supply their products to the market.”

Samsung BioLogics received FDA approval for its first mAb at the site in December last year​, which was followed by the European Medicines Agency’s (EMA) approval​ for the same drug substance.

The firm’s 152,000L facility – commissioned in 2013​ – has recently been joined by ‘Plant 3’, which is expected to surpass Samsung BioLogics’ second plant as the largest biomanufacturing facility in the world.

The $740m facility was completed in December 2017​ and is awaiting validation. The site will add a further 180,000L of capacity, taking Samsung BioLogics’ mammalian cell culture capacity to 362,000L.

The CDMO attracted​ regulatory attention earlier this month when it threatened to sue the Korean government after news of an accounting probe decreased its value by $6bn.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers